Latigo Biotherapeutics (NASDAQ:LTGO) Shares Down 6.3% – Here’s Why

Posted by Brian Himes on Oct 25th, 2026

Shares of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report) were down 6.3% on Friday. The company traded as low as $15.49 and last traded at $15.53. Approximately 41,025 shares were traded during trading, a decline of 86% from the average daily volume of 296,637 shares. The stock had previously closed at $16.57.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Guggenheim assumed coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $50.00 target price on the stock. Wall Street Zen cut shares of Latigo Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Jefferies Financial Group assumed coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price target for the company. The Goldman Sachs Group assumed coverage on shares of Latigo Biotherapeutics in a research note on Tuesday, September 1st. They set a “buy” rating and a $73.00 price objective for the company. Finally, Leerink Partners initiated coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They set an “outperform” rating and a $36.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $52.25.

Get Our Latest Analysis on LTGO

Latigo Biotherapeutics Trading Down 9.4%

The firm has a 50-day moving average price of $19.50. The stock has a market cap of $995.83 million and a price-to-earnings ratio of -0.28.

Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last posted its earnings results on Thursday, September 3rd. The company reported ($27.59) earnings per share (EPS) for the quarter.

Insider Transactions at Latigo Biotherapeutics

In other Latigo Biotherapeutics news, Director James Tananbaum purchased 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the director owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of the stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the transaction, the insider directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This represents a 7.49% increase in their position. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics Company Profile

(Get Free Report)

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing non-opioid treatments for pain. The company focuses on therapies designed to selectively target Nav1.8, a sodium channel expressed in peripheral sensory neurons that plays an important role in the transmission of pain signals.

Latigo’s lead product candidate, LTG-001, is an oral, selective Nav1.8 inhibitor being developed for the treatment of acute and chronic pain conditions. By targeting pain signaling outside the central nervous system, the company aims to develop alternatives to opioid medicines and other pain treatments that may carry significant safety or tolerability concerns.